US6841255B2 - Biocompatible polymer film - Google Patents

Biocompatible polymer film Download PDF

Info

Publication number
US6841255B2
US6841255B2 US10/245,115 US24511502A US6841255B2 US 6841255 B2 US6841255 B2 US 6841255B2 US 24511502 A US24511502 A US 24511502A US 6841255 B2 US6841255 B2 US 6841255B2
Authority
US
United States
Prior art keywords
film
polymer
polylactone
forming
hydrophobic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/245,115
Other versions
US20030059620A1 (en
Inventor
Reinhold Deppisch
Ulrich Bauer
Werner Beck
Ruth Dietrich
Hermann Göhl
Katja Krämer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gambro Lundia AB
Original Assignee
Gambro AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gambro AB filed Critical Gambro AB
Priority to US10/245,115 priority Critical patent/US6841255B2/en
Assigned to GAMBRO AB reassignment GAMBRO AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KRAMER, KATJA, DEPPISCH, REINHOLD, GOHL, HERMANN, BAUER, ULRICH, BECK, WERNER, DIETRICH, RUTH
Publication of US20030059620A1 publication Critical patent/US20030059620A1/en
Application granted granted Critical
Publication of US6841255B2 publication Critical patent/US6841255B2/en
Assigned to CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT reassignment CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT SECURITY AGREEMENT Assignors: GAMBRO AB
Assigned to GAMBRO LUNDIA AB reassignment GAMBRO LUNDIA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAMBRO AB
Assigned to GAMBRO LUNDIA AB reassignment GAMBRO LUNDIA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAMBRO AB
Assigned to GAMBRO AB reassignment GAMBRO AB RELEASE OF SECURITY INTEREST IN PATENTS Assignors: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
Assigned to GAMBRO LUNDIA AB reassignment GAMBRO LUNDIA AB RELEASE OF SECURITY INTEREST IN PATENTS Assignors: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06Use of macromolecular materials
    • A61L33/068Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/18Manufacture of films or sheets
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31551Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
    • Y10T428/31598Next to silicon-containing [silicone, cement, etc.] layer

Definitions

  • the present invention relates to the basic problem that many of the biomedical devices used in contact with live tissue or body fluids are made of materials of synthetic or natural origin which are not biocompatible. Lack of biocompatibility can lead to blood clotting as well as various other manifestations of inflammation and tissue activation.
  • microbial infection can establish themselves on device surfaces. Infectious agents such as bacteria that colonize and form biofilms on surfaces can prove exceedingly difficult to eradicate, [Costerton, J. W. et al. (1999) Science 284:1318-1322].
  • Devices intended for long-term contact such as implanted stents or indwelling catheters can also serve as a surface for host cell adhesion, permitting host cells to become activated, proliferate or to alter normal physiological function and to restrict function or intended use of a device, for example by restricting fluid flow through the device.
  • U.S. Pat. No. 4,872,867 discloses modifying a polyurethane with a water soluble polymer and crossing them in situ with a silane-type coupling agent to form a cross-linked and intertwined polysiloxane network.
  • U.S. Pat. No. 4,636,552 discloses a polydimethyl siloxane with polylactone side chains which are said to be useful for imparting biocompatibility when combined with a base polymer, or used to replace plasticizer.
  • 4,929,510 discloses a diblock copolymer having a more hydrophobic block and a less hydrophobic block.
  • a solution of the diblock copolymer in a solvent which swells the matrix polymer is used to introduce the diblock into an article of matrix polymer. Thereafter, the article is transferred to water, to force orientation of the incorporated diblock copolymer such that the more hydrophobic block is embedded in the matrix and the less hydrophobic block is exposed on the surface of the article.
  • Examples of diblock copolymers included poly (ethyleneoxide-propylene oxide), N-vinyl-pyrrolidone-vinyl acetate and N-vinyl-pyrrolidone-styrene.
  • 4,663,413 and 4,675,361 disclose segmented block copolymers, in particular polysiloxane-polycaprolactone linear block copolymers. The latter were incorporated into base polymer material to modify the surface properties thereof. Although initially blended in bulk into the base polymer, the copolymer migrates to the surface to form an exceptionally thin, possibly a monolayer film which imparts the desired surface characteristic, specifically, biocompatibility.
  • Triblock copolymers having a polydimethyl siloxane (PDMS) block flanked by polylactone (PL) blocks have been described, Lovinger, A. J. et al. (1993) J. Polymer Sci . Part B. ( Polymer Physics ) 31:115-123.
  • PDMS polydimethyl siloxane
  • PL polylactone
  • PL-PDMS-PL triblock copolymers are commercially available, for example from Thoratec Laboratories, Berkeley, Calif., which provides a series of such polymers designated “SMA” in which the siloxane is dimethyl siloxane and the lactone is caprolactone, and also from Th. Goldschmidt A G, Essen Germany, under the name “Tegomer” (Trademark, Goldschmidt A G).
  • SMA siloxane
  • Tegomer Trafficschmidt A G
  • the nominal molecular weights (number average) of the polysiloxane blocks suitable for use herein range from about 1000 to about 5000, while the nominal molecular weights of the caprolactone blocks range from about 1000 to about 10,000.
  • Tsai, C-C. et al (1994) ASAIO Journal 40:M619-M824 reported comparative studies with PL-PDMS-PL blended into polyvinyl chloride and other base polymers or applied as a coating thereon.
  • U.S. Pat. No. 5,589,563 discloses polymers having surface-modifying end groups, for example, polyurethanes having hard segments and soft segments covalently bonded to end groups such as PDMS or aromatic polycarbonates.
  • the surface-modifying end groups tend to concentrate on the polymer surface to increase the surface hydrophobicity.
  • the invention includes a co-polymer film and method for improving the biocompatibility of any article of synthetic/polymeric, organic or metallic origin intended to contact blood, tissue or body fluids in the course of a medical treatment or procedure.
  • articles include, without limitation, tubing, bags, catheters, stents, probes, feeding tubes, drainage lines, vascular grafts, artificial shunts and the like whether intended for long-term or short-term contact with blood, tissue or other body fluid or their plasma or corpuscular and cellular constituents.
  • the co-polymer film of the invention provides reduced thrombogenicity, reduced bacterial growth and adhesion, reduced toxicity to host cells, and infiltration and seeding with inflammatory cells or host cells, when compared to articles or materials in conventional use or without the polymer film described.
  • FIG. 1 Sccanning electron microscopy of a catheter tube cross section having BaSO 4 incorporated into the catheter material for enhanced x-ray contrast.
  • the interior, blood contacting surface is uppermost.
  • the arrow designates a PUR-SMA film applied to the inner surface of the base material.
  • FIG. 2 Atomic force microscopy scans of single component PUR (top row) and PUR coated with a PUR-SMA film. Left row shows height variations, right row shows phase variations associated with drag on the probe tip. Light and dark areas have different physico-chemical characteristics, the light areas indicating a more soft and hydrophilic surface character, the dark areas indicating a surface that is relatively hard, hydrophobic and associated with a higher surface concentration of PDMS.
  • FIG. 3 Atomic force microscopy comparing surfaces of a two component PUR (top row) and a coating of 2 component PUR with SMA. Height and phase images, left and right respectively, are as described for FIG. 2 .
  • FIG. 4 Bacterial colonization of polyurethane test plates uncoated (row 3) and coated with PUR-PL-PDMS-PL film (row 2) and films of PUR (row 5) and Pul-PL-PDMS-PL coplymer (row 6).
  • FIG. 5 Bar graph showing cell toxicity (inhibition of cell growth) of extracts of coated catheters with and without pre-coating as described below and in Example 8.
  • the present invention includes a co-polymer film which can be applied over a surface of an article to form a continuous surface that is more biocompatible and has a smoother surface morphology than an untreated article.
  • the co-polymer film of the invention can be formed by providing a hydrophobic polymer block, such as polydimethylsiloxane (PDMS) with functional —OH end groups and reacting the —OH ends with a conventional monomer or prepolymer of a film-forming polymer capable of reacting with —OH groups.
  • PDMS polydimethylsiloxane
  • Such reactions are exemplified, using as reactive PDMS a triblock copolymer of the polylactone-polysiloxane-polylactone (PL-PDMS-PL) type, or silicone polyesters.
  • the —OH groups of the polylactone blocks can react with any of a variety of isocyanates in a suitable solvent to form a polymer having PDMS incorporated with its structure.
  • the film can be applied to the surface of an article by any convenient means of coating the article with the reaction mixture in solvent, and allowing the solvent to evaporate.
  • a polymeric film having PDMS blocks incorporated within the polymer forms over the coated surface.
  • the resulting film is mechanically stronger than coatings of PL-PDMS-PL alone.
  • the film integrity makes it possible to encase any structure made of any material compatible with solvents used to dissolve the starting materials. Materials can be chosen for their optimal mechanical properties, then an article made of the desired material can be encased in a polymeric film of the invention to render the article biocompatible.
  • the polymeric films of the invention are further advantageous in that they can reduce surface roughness which may exist in the article. As an example, in polyurethane-based catheters, barium sulfate is added to provide x-ray contrast.
  • the barium sulfate increases the surface roughness, which can degrade the biocompatibility, induce flow turbulence or enhance cellular or microbial deposits.
  • the polymer film applied to the catheter surface not only increases the biocompatibility by changing the chemical composition of the surface, but also by reducing the roughness of the surface.
  • Other types of surface roughness such as are introduced during fabrication, e.g. by injection molding or by extrusion or by thermal processes during tip shaping or by mechanical manufacturing steps such as mechanical or LASER based hole drilling, can be reduced by applying a polymer film of the invention.
  • the type of surface that provides the least opportunity for interaction is therefore considered to be one which presents a patchy surface with domains of varying character smaller than the corresponding interacting domains commonly found on proteins, cells and the like.
  • the co-polymer films of the invention are characterized by a non-uniform surface having domains of varied properties.
  • the characteristics associated with such domains include hydrophobic/hydrophilic, rough/smooth, hard/soft, and the like.
  • Optimal sizes lie in the range from 0.1-100 nm of average diameter, although boundaries need not be regular or precisely delineated, domain size need not be uniform and domains outside the optimal range are functional. Surfaces having such optimal patchiness do not provide a sufficient contact area for any given surface trait to allow non-specific binding of biological materials.
  • the invention therefore includes a co-polymer film generated by reaction of a hydrophobic polymer block, for example a PDMS-containing block copolymer having reactive —OH groups, with a monomer or prepolymer of a film-forming polymer, for example, an isocyanate or isocyanate-polyol mixture.
  • a hydrophobic polymer block for example a PDMS-containing block copolymer having reactive —OH groups
  • a monomer or prepolymer of a film-forming polymer for example, an isocyanate or isocyanate-polyol mixture.
  • Suitable hydrophobic polymer blocks include various siloxane polymers, fluoropolymers, polyethyleneglycol-polydimethylsiloxane copolymers, silicone polyesters, polyamides, polysulfones, polyarlyethersulfone, polycarbonates, polyolefins including cycloolefine-copolymers and the like.
  • Block-copolymers can be applied for coating films according to the described invention.
  • Reactive end groups on the hydrophobic polymer block can be any sort of reactive group suitable for coupling the hydrophobic polymer block with monomer or prepolymer units of the film-forming polymer.
  • coupling agents can be used to react with the hydrophobic block and then with monomer or prepolymer units of the film-forming polymer.
  • film-forming polymers include polyurethanes, polyolefins, polycarbonates, polyvinyl chlorides polyamides, polysulfones, polyarylethersulfones, cellulosic polymers, cycloolefin-copolymers and the like.
  • PUR polyurethanes
  • PL-PDMS-PL has —OH groups which allow it to be incorporated internally into a polyurethane by reaction with free isocyanate groups.
  • the invention also provides a method of coating an article with a polymer film, by applying the products of the described reaction in a solvent over the surface of the article and removing the solvent, whereby the film is formed as the solvent is removed.
  • the invention is exemplified by two types of polymer film; using a commercially available PL-PDMS-PL block copolymer such as SMA 422, SMA 423 or SMA 425 (Trademark, Thoratec Laboratories Corp., Berkeley, Calif.) or a silicone polyester such as Tegomer H-Si 6440 (Trademark, Th. Goldschmidt A. G., Essen, Germany) in either a one component reaction with a polyurethane prepolymer (Desmodur E22 or E23, Trademark, Bayer Corp.) or a two-component reaction with an isocyanate, PL-PDMS-PL block copolymer and a polyol. In both reactions, PL-PDMS-PL blocks react as bifunctional units that become incorporated internally in the PUR polymer chain.
  • PL-PDMS-PL block copolymer such as SMA 422, SMA 423 or SMA 425 (Trademark, Thoratec Laboratories Corp., Berkeley, Calif.) or
  • reaction conditions can be varied so as to control the proportion of hydrophobic blocks to polyurethane.
  • a preferred molar ratio of OH/NCO endgroups is in the range of 0.1 to 10. Reaction conditions which tend to increase the proportion of the hydrophobic block also tend to increase the overall hydrophobicity of the resulting film, and to increase the average diameter of the hydrophobic patches.
  • biocompatibility can be improved by providing an interlayer between the surface of the article and the coating film.
  • the interlayer can be formed of a hydrophobic material having free —OH groups such as polyol or one that is also a component of the coating film, such as PL-PDMS-PL (also referred to by trade names herein as SMA or Tegomer).
  • the interlayer e.g. PL-PDMS-PL can be applied by painting or immersing the article to be coated in a solution of PL-PDMS-PL dissolved in a suitable solvent, for example methyl-isobutyl ketone, then allowing the solvent to evaporate.
  • the process termed pre-coating, yields a layer of PL-PDMS-PL which can subsequently be coated with a polymer film of the invention, such that the PL-PDMS-PL coating forms an interlayer between the surface of the article and the polymer coating.
  • Formation of an interlayer can be advantageous for reducing cell toxicity of coated articles, such as catheters, especially where the catheter is made of a polyurethane base polymer having leachable isocyanates.
  • Multilayered films can also be prepared to provide a composite of physical properties not available from a single-layer coating.
  • OH-groups on PL-PDMS-PL are well-known in the art and can be exploited for incorporating hydrophobic blocks into a film-forming polymer.
  • the reaction for PL-PDMS-PL can be augmented by reaction with coupling reagents which can then react with functional groups present in other polymers or monomers.
  • Coupling to monomers or prepolymers having —OH functional groups can be carried out using alkyl or aryl sulfonates, e.g. tosylchloride which can be reacted with the monomer or prepolymer, R—OH, then substituted by a OH-group of PL-PDMS-PL.
  • Monomers or prepolymers having an amine, thiol or alcohol functional group can be activated by cyanuric chloride, then coupled to PL-PDMS-PL.
  • Monomers or prepolymers having an epoxy group can be reacted directly with the OH groups of PL-PDMS-PL.
  • Other coupling agents include anhydrides such as maleic anhydride or maleic acid anhydride copolymer, active esters such as N-hydroxy succinimide and esters of carboxylic acids or carboxylic acids activated by various carbodiimides. In general, a wide variety of such coupling reactions is known in the art and can be exploited to incorporate hydrophobic blocks into film-forming polymers, using known reaction conditions.
  • thrombogenicity assessment using freshly donated human blood.
  • TAT thrombin-anti-thrombin III complex
  • Thrombin is the major component in the coagulation circuit, since thrombin is a potent activator for platelets and cleaves fibrinogen to fibrin, which finally leads to a polymerized network, i.e. a clot.
  • TAT was measured by a commercially available ELISA test according to the instruction of the manufacturer (Behring Co., Germany). The comparison of materials/surfaces is done in direct comparison of the modified versus the non-modified polymer system. Accelerated reaction kinetics for TAT indicates less biocompatible, more thrombogenic material.
  • Non-treated 2 251 1570 clot already formed Treated (60% solvent/ 1 73 605 1313 5% SMA, 35% E22 Treated (50% solvent/ 1 1 54 65 5% SMA, 45% E22
  • Non-modified and SMA-modified films on catheter tubes prepared as cross-cuts were sputter coated with a thin Pt/Au layer and analyzed in a Philips electron microscope. As shown in FIG. 1 , a coating film of approximately 20 ⁇ m forms labeled “SMA-PUR coating.” The coating process allows variation of the film thickness optimally from about 0.1 ⁇ m to several 100 ⁇ m. Furthermore, SEM also identifies small white spots which are due to the addition of BaSO 4 into the catheter material. BaSO 4 gives a change in emission of electrons in SEM. FIG. 1 shows a clear separation of the BaSO 4 from the blood contacting surface. As a conclusion: coated, blood-contacting surface lacks roughness due to BaSO 4 crystals, there is no release of BaSO 4 into blood, instead BaSO 4 remains in the catheter material.
  • Atomic force microscopy is the most powerful technique to analyze nano-structures consisting of patches with different chemical or physico-chemical properties.
  • the AFM analysis was performed applying tapping mode technique with low forces on the tip of the cantilever (reference for methods: Magonov et al. (1996) in Surface Analysis with STM and AFM , VCH, Weinheim), see FIG. 2 and FIG. 3 .
  • the pictures of the surfaces taken or generated by AFM in tapping show different spots in the size of nanometers (10-100 nm in diameter).
  • the picture defined as height image shows a kind of depth profile
  • the picture defined as phase shift image shows the phase shift when the cantilever or tip is ‘scratching’ or moving on the surfaces (e.g. due to chemical forces or different softness).
  • Light areas are more soft and hydrophilic. Darker areas have higher PDMS and are harder.
  • Test plates were made of Tecoflex EG60DB20 (Thermedics, Inc., Woburn, Mass.) a thermoplastic, aliphatic polyurethane synthesized of methylene bis (cyclohexyl) diisocyanate (40%), polytetramethylene ether glycol (9.6%) and 1,4 diol chain extender (30.4%) with barium sulfate (20.0%) to impart x-ray opacity.
  • Coating material was a one-component polyurethane essentially as in Example 1 formed from 35% Demodur E22, 5% PL-PDMS-PL (Tegomer) and 60% methyl isobutyl ketone (MIBK), cast as a film or coated on the Tecoflex test plates.
  • Test plates or films were exposed to a viable culture of S. epidermis for a period of 48 hours, with absorbance readings every twenty minutes.
  • Results are shown in FIG. 4 .
  • Optical density is plotted on the vertical axis against time on the horizontal axis, for a series of test replicates A-F.
  • Uncoated plates (row 3) rapidly and reproducibly supported increasing density of adherent bacteria. Coated plates over the same time interval did not support measurable bacterial adherence. Films formed of polyurethane alone did not support measurable adherence. Co-polymer films of PUR and PL-PDMS-PL significantly retarded the adherence of bacteria compared to uncoated test plates, by an average of about 30 hours for the same optical density. Surprisingly the presence of PDMS at the surface reduces in a dose-dependent manner the bacterial adhesion and proliferation.
  • ICG inhibition of cell growth
  • the ICG test was begun by seeding a 96-well tissue culture plate with 1500-2000 mouse fibroblast cells (strain L-929) previously grown to subconfluence for 48-72 h in complete Eagles MEM. The plates were incubated for 24 h at 37° C. The medium was then removed and test eluates were added. The test eluates were made by incubating test plates or films in distilled water (1 ml for each 10 cm 2 test material) at 70° C. for 24 h.
  • the stock solution is diluted 10-fold and pH adjusted to 7.2.
  • Toxicity was also reduced or eliminated by interposing an interlayer of polyol or PL-SMA-PL over the test material, prior to applying the co-polymer film.
  • Test catheters were pre-coated with either 0.125% or 1.0% PL-PDMS-PL by applying the pre-coating in a solution of methyl-isobutyl ketone and curing at 40° C. to remove the solvent.
  • Test catheters were then coated with co-polymer essentially as described in Example 1 except the co-polymer starting solution was 45% Desmodur E23, 5% PL-PDMS-PL and 50% MBK. The data are shown in FIG. 5 .
  • toxicity can be reduced either by interposing an interlayer having free-OH groups, or by employing rapidly reacting components to form the co-polymer film. Either strategy avoids or minimizes the possibility of reaction between the reaction components of the co-polymer film and the base polymer of which the article to be coated is formed. This multilayer concept as described above allows a great flexibility in composing the polymers.
  • Fibroblast cells were inoculated on a tissue culture plate pre-coated on the bottom with a co-polymer film of the invention, a portion of which was overlaid by a glass plate with the entire apparatus bathed in growth medium. Growth on the co-polymer surface was compared to growth on the glass surface. Cells grew on the glass surface but failed to attach or proliferate on the co-polymer surface. The failure of cells to attach or proliferate on co-polymer film surfaces of the invention indicates that such surfaces are unlikely to be damaged when implanted, by ingrowth or overgrowth of host cell tissue.

Abstract

The present invention includes a co-polymer film which can be applied over a surface of an article to form a continuous surface that is more biocompatible and has a smoother surface morphology than an untreated article. In general the co-polymer film of the invention can be formed by providing a hydrophobic polymer block, such as polydimethylsiloxane (PDMS) with functional —OH end groups and reacting the —OH ends with a conventional monomer or prepolymer of a film-forming polymer capable of reacting with —OH groups. Such reactions are exemplified, using as reactive PDMS a triblock copolymer of the polylactone-polysiloxane-polylactone (PL-PDMS-PL) type, or silicone polyesters. The —OH groups of the polylactone blocks can react with any of a variety of isocyanates in a suitable solvent to form a polymer having PDMS incorporated with its structure. The film can be applied to the surface of an article by any convenient means of coating the article with the reaction mixture in solvent, and allowing the solvent to evaporate.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of U.S. patent application Ser. No. 09/415,943 filed Oct. 8, 1999, now U.S. Pat. No. 6,500,549, which claims priority from U.S. Provisional Application No. 60/104,001 filed Oct. 13, 1998.
BACKGROUND OF THE INVENTION
The present invention relates to the basic problem that many of the biomedical devices used in contact with live tissue or body fluids are made of materials of synthetic or natural origin which are not biocompatible. Lack of biocompatibility can lead to blood clotting as well as various other manifestations of inflammation and tissue activation.
In addition, microbial infection can establish themselves on device surfaces. Infectious agents such as bacteria that colonize and form biofilms on surfaces can prove exceedingly difficult to eradicate, [Costerton, J. W. et al. (1999) Science 284:1318-1322]. Devices intended for long-term contact such as implanted stents or indwelling catheters can also serve as a surface for host cell adhesion, permitting host cells to become activated, proliferate or to alter normal physiological function and to restrict function or intended use of a device, for example by restricting fluid flow through the device.
An approach used in the prior art to improve biocompatibility has been based on modifying the surface of a device to make it more hydrophobic. On the other hand increased biocompatibility at least in part can be achieved by making a surface more hydrophilic. Although certain types of polymers, such as silicones and siloxanes, are known to possess many attributes of biocompatibility, there are no reliable physical correlates which enable one to predict biocompatibility with any degree of certainty. Generally, hydrophobic surfaces are more biocompatible than hydrophilic surfaces. Zisman's critical surface tension [Zisman, W. A., (1964) Adv. Chem: Ser. 43] has been used as a parameter to help assess potential biocompatibility. Materials with an optimum critical surface tension are frequently biocompatible, yet there are notable exceptions. For example, polyethylene and polypropylene have critical surface tensions well within the optimum range, but they are not predictably biocompatible. Other factors are also important. Without a clear understanding of the nature of these factors, biocompatibility remains unpredictable.
Because of the attractive structural properties of polyolefins and polyurethanes, various blending and copolymerization techniques have been developed to impart greater biocompatibility. U.S. Pat. No. 4,872,867 discloses modifying a polyurethane with a water soluble polymer and crossing them in situ with a silane-type coupling agent to form a cross-linked and intertwined polysiloxane network. U.S. Pat. No. 4,636,552 discloses a polydimethyl siloxane with polylactone side chains which are said to be useful for imparting biocompatibility when combined with a base polymer, or used to replace plasticizer. U.S. Pat. No. 4,929,510 discloses a diblock copolymer having a more hydrophobic block and a less hydrophobic block. A solution of the diblock copolymer in a solvent which swells the matrix polymer is used to introduce the diblock into an article of matrix polymer. Thereafter, the article is transferred to water, to force orientation of the incorporated diblock copolymer such that the more hydrophobic block is embedded in the matrix and the less hydrophobic block is exposed on the surface of the article. Examples of diblock copolymers included poly (ethyleneoxide-propylene oxide), N-vinyl-pyrrolidone-vinyl acetate and N-vinyl-pyrrolidone-styrene. U.S. Pat. Nos. 4,663,413 and 4,675,361 disclose segmented block copolymers, in particular polysiloxane-polycaprolactone linear block copolymers. The latter were incorporated into base polymer material to modify the surface properties thereof. Although initially blended in bulk into the base polymer, the copolymer migrates to the surface to form an exceptionally thin, possibly a monolayer film which imparts the desired surface characteristic, specifically, biocompatibility.
Triblock copolymers having a polydimethyl siloxane (PDMS) block flanked by polylactone (PL) blocks have been described, Lovinger, A. J. et al. (1993) J. Polymer Sci. Part B. (Polymer Physics) 31:115-123. Such triblock copolymers have been incorporated into bulk formulations, and also applied as surface coatings, to reduce thrombogenicity, as described in U.S. Pat. No. 5,702,823, incorporated herein by reference. PL-PDMS-PL triblock copolymers are commercially available, for example from Thoratec Laboratories, Berkeley, Calif., which provides a series of such polymers designated “SMA” in which the siloxane is dimethyl siloxane and the lactone is caprolactone, and also from Th. Goldschmidt A G, Essen Germany, under the name “Tegomer” (Trademark, Goldschmidt A G). The nominal molecular weights (number average) of the polysiloxane blocks suitable for use herein range from about 1000 to about 5000, while the nominal molecular weights of the caprolactone blocks range from about 1000 to about 10,000. Tsai, C-C. et al (1994) ASAIO Journal 40:M619-M824, reported comparative studies with PL-PDMS-PL blended into polyvinyl chloride and other base polymers or applied as a coating thereon.
Deppisch, R. et al. (1998) Nephrol. Dial. Transplant. 13:1354-1359 reported improved thrombogenic properties for films or membrane structures of polyamide-polyvinyl-pyrrolidone, polyamide-polyarylethersulfone-polyvinylpyrrolidone or polyarylether-polyvinylpyrrolidone. Improved thrombogenic properties were attributed to a microdomain surface structure of hydrophobic and hydrophilic surface patches.
U.S. Pat. No. 5,589,563 discloses polymers having surface-modifying end groups, for example, polyurethanes having hard segments and soft segments covalently bonded to end groups such as PDMS or aromatic polycarbonates. The surface-modifying end groups tend to concentrate on the polymer surface to increase the surface hydrophobicity.
More recently, it has been recognized that the interactions between biological substances and man-made materials leading to clotting, inflammatory responses and microbial and host cell reactions are more complex processes in which the surface hydrophobicity of the man-made material is but one factor. Interactions between biological materials and foreign substances have been shown to include, at a minimum, molecular interactions with components of the complement system, with the kallikrein-kinin system, with the intrinsic pathway of coagulation initiation, with platelet and with other cellular components of blood including peripheral blood cells, e.g. monocytes and granulocytes.
In addition, microbial growth and host cell activation and/or proliferation on the polymer surface are problems with potentially serious consequences, especially for implanted or indwelling articles such as catheters and stents. The design of materials having improved biocompatibility must take such factors into account.
SUMMARY OF THE INVENTION
The invention includes a co-polymer film and method for improving the biocompatibility of any article of synthetic/polymeric, organic or metallic origin intended to contact blood, tissue or body fluids in the course of a medical treatment or procedure. Such articles include, without limitation, tubing, bags, catheters, stents, probes, feeding tubes, drainage lines, vascular grafts, artificial shunts and the like whether intended for long-term or short-term contact with blood, tissue or other body fluid or their plasma or corpuscular and cellular constituents. The co-polymer film of the invention provides reduced thrombogenicity, reduced bacterial growth and adhesion, reduced toxicity to host cells, and infiltration and seeding with inflammatory cells or host cells, when compared to articles or materials in conventional use or without the polymer film described.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1—Scanning electron microscopy of a catheter tube cross section having BaSO4 incorporated into the catheter material for enhanced x-ray contrast. The interior, blood contacting surface is uppermost. The arrow designates a PUR-SMA film applied to the inner surface of the base material.
FIG. 2—Atomic force microscopy scans of single component PUR (top row) and PUR coated with a PUR-SMA film. Left row shows height variations, right row shows phase variations associated with drag on the probe tip. Light and dark areas have different physico-chemical characteristics, the light areas indicating a more soft and hydrophilic surface character, the dark areas indicating a surface that is relatively hard, hydrophobic and associated with a higher surface concentration of PDMS.
FIG. 3—Atomic force microscopy comparing surfaces of a two component PUR (top row) and a coating of 2 component PUR with SMA. Height and phase images, left and right respectively, are as described for FIG. 2.
FIG. 4—Bacterial colonization of polyurethane test plates uncoated (row 3) and coated with PUR-PL-PDMS-PL film (row 2) and films of PUR (row 5) and Pul-PL-PDMS-PL coplymer (row 6). Horizontal axis:time (24 hrs. maximum); vertical axis, optical density at 578 nm. Letters along vertical axis identify separate test plates.
FIG. 5—Bar graph showing cell toxicity (inhibition of cell growth) of extracts of coated catheters with and without pre-coating as described below and in Example 8.
DETAILED DESCRIPTION OF THE INVENTION
The present invention includes a co-polymer film which can be applied over a surface of an article to form a continuous surface that is more biocompatible and has a smoother surface morphology than an untreated article. In general the co-polymer film of the invention can be formed by providing a hydrophobic polymer block, such as polydimethylsiloxane (PDMS) with functional —OH end groups and reacting the —OH ends with a conventional monomer or prepolymer of a film-forming polymer capable of reacting with —OH groups. Such reactions are exemplified, using as reactive PDMS a triblock copolymer of the polylactone-polysiloxane-polylactone (PL-PDMS-PL) type, or silicone polyesters. The —OH groups of the polylactone blocks can react with any of a variety of isocyanates in a suitable solvent to form a polymer having PDMS incorporated with its structure. The film can be applied to the surface of an article by any convenient means of coating the article with the reaction mixture in solvent, and allowing the solvent to evaporate.
A polymeric film having PDMS blocks incorporated within the polymer forms over the coated surface. The resulting film is mechanically stronger than coatings of PL-PDMS-PL alone. The film integrity makes it possible to encase any structure made of any material compatible with solvents used to dissolve the starting materials. Materials can be chosen for their optimal mechanical properties, then an article made of the desired material can be encased in a polymeric film of the invention to render the article biocompatible. The polymeric films of the invention are further advantageous in that they can reduce surface roughness which may exist in the article. As an example, in polyurethane-based catheters, barium sulfate is added to provide x-ray contrast. The barium sulfate increases the surface roughness, which can degrade the biocompatibility, induce flow turbulence or enhance cellular or microbial deposits. The polymer film applied to the catheter surface not only increases the biocompatibility by changing the chemical composition of the surface, but also by reducing the roughness of the surface. Other types of surface roughness, such as are introduced during fabrication, e.g. by injection molding or by extrusion or by thermal processes during tip shaping or by mechanical manufacturing steps such as mechanical or LASER based hole drilling, can be reduced by applying a polymer film of the invention.
Without intending to be bound by a particular theory of operation, data is provided herewith demonstrating that the polymer film of the invention has surface characteristics that are consistent with current understanding regarding biocompatible surfaces. Such current understanding takes note of the fact that cells, proteins and other biological materials interact nonspecifically with surfaces in a variety of ways, including hydrophobic, hydrophilic, and ionic or electrostatic interactions, the binding often being of a cooperative nature. A review of such interactions is found in Deppisch, R. al. (1998) Nephrol. Dial. Transplant 13:1354-1359, which is incorporated herein by reference. The type of surface that provides the least opportunity for interaction is therefore considered to be one which presents a patchy surface with domains of varying character smaller than the corresponding interacting domains commonly found on proteins, cells and the like. The co-polymer films of the invention are characterized by a non-uniform surface having domains of varied properties. The characteristics associated with such domains include hydrophobic/hydrophilic, rough/smooth, hard/soft, and the like. Optimal sizes lie in the range from 0.1-100 nm of average diameter, although boundaries need not be regular or precisely delineated, domain size need not be uniform and domains outside the optimal range are functional. Surfaces having such optimal patchiness do not provide a sufficient contact area for any given surface trait to allow non-specific binding of biological materials. The surfaces of polymer-films of the present invention have been analyzed by atomic force microscopy (AFM). The results, presented herein, demonstrate that the exemplified such films possess a patchy surface with domains of varied hydrophobicity and hardness which have average diameters in the range 0.1-100 nm.
Also presented herewith are data demonstrating significantly increased biocompatibility of surfaces covered by a polymer film of the invention, compared to an uncoated surface.
The invention therefore includes a co-polymer film generated by reaction of a hydrophobic polymer block, for example a PDMS-containing block copolymer having reactive —OH groups, with a monomer or prepolymer of a film-forming polymer, for example, an isocyanate or isocyanate-polyol mixture. There are many ways of forming a co-polymer film according to the invention. Suitable hydrophobic polymer blocks include various siloxane polymers, fluoropolymers, polyethyleneglycol-polydimethylsiloxane copolymers, silicone polyesters, polyamides, polysulfones, polyarlyethersulfone, polycarbonates, polyolefins including cycloolefine-copolymers and the like. Basically all kinds of block-copolymers can be applied for coating films according to the described invention. Reactive end groups on the hydrophobic polymer block can be any sort of reactive group suitable for coupling the hydrophobic polymer block with monomer or prepolymer units of the film-forming polymer. Alternatively, coupling agents can be used to react with the hydrophobic block and then with monomer or prepolymer units of the film-forming polymer.
Examples of film-forming polymers include polyurethanes, polyolefins, polycarbonates, polyvinyl chlorides polyamides, polysulfones, polyarylethersulfones, cellulosic polymers, cycloolefin-copolymers and the like. Preferred are polyurethanes (PUR) which can be formed by reaction of isocyanate with a polyol. PL-PDMS-PL has —OH groups which allow it to be incorporated internally into a polyurethane by reaction with free isocyanate groups.
The invention also provides a method of coating an article with a polymer film, by applying the products of the described reaction in a solvent over the surface of the article and removing the solvent, whereby the film is formed as the solvent is removed.
The invention is exemplified by two types of polymer film; using a commercially available PL-PDMS-PL block copolymer such as SMA 422, SMA 423 or SMA 425 (Trademark, Thoratec Laboratories Corp., Berkeley, Calif.) or a silicone polyester such as Tegomer H-Si 6440 (Trademark, Th. Goldschmidt A. G., Essen, Germany) in either a one component reaction with a polyurethane prepolymer (Desmodur E22 or E23, Trademark, Bayer Corp.) or a two-component reaction with an isocyanate, PL-PDMS-PL block copolymer and a polyol. In both reactions, PL-PDMS-PL blocks react as bifunctional units that become incorporated internally in the PUR polymer chain.
The reaction conditions can be varied so as to control the proportion of hydrophobic blocks to polyurethane. A preferred molar ratio of OH/NCO endgroups is in the range of 0.1 to 10. Reaction conditions which tend to increase the proportion of the hydrophobic block also tend to increase the overall hydrophobicity of the resulting film, and to increase the average diameter of the hydrophobic patches.
As a further aspect of the invention, biocompatibility, particularly reduced cell toxicity, can be improved by providing an interlayer between the surface of the article and the coating film. The interlayer can be formed of a hydrophobic material having free —OH groups such as polyol or one that is also a component of the coating film, such as PL-PDMS-PL (also referred to by trade names herein as SMA or Tegomer). The interlayer, e.g. PL-PDMS-PL can be applied by painting or immersing the article to be coated in a solution of PL-PDMS-PL dissolved in a suitable solvent, for example methyl-isobutyl ketone, then allowing the solvent to evaporate. The process, termed pre-coating, yields a layer of PL-PDMS-PL which can subsequently be coated with a polymer film of the invention, such that the PL-PDMS-PL coating forms an interlayer between the surface of the article and the polymer coating. Formation of an interlayer can be advantageous for reducing cell toxicity of coated articles, such as catheters, especially where the catheter is made of a polyurethane base polymer having leachable isocyanates. Multilayered films can also be prepared to provide a composite of physical properties not available from a single-layer coating.
EXAMPLE 1
Step 1:
    • 25 g Methylisobutylketone
    • 1.5 g SMA 422 (Thoratec Corp.)
    • Warm up to 40° C. under light stirring, approximately 5 min.
      • SMA 422 is a triblock co-polymer of polycaprolactone-polydimethylsiloxane-polycaprolactone blocks having nominal molecular weights of 4000, 2000 and 4000 respectively.
        Step 2:
    • Add 23.5 g Desmodur E22 (Bayer Co.)
    • Light stirring to avoid air bubble formation. Reaction can be carried out for up to two hours, in temperature range 0° C.-60° C.
    • Degassing
      • Desmodur E22 is a polyisocyanate prepolymer based on diphenyl methane diisocyanate. The —NCO content is 8.6% by weight. Equivalent weight is 488.
        Step 3:
    • (a) Casting a film in various thickness on glass plate with a casting knife with or without support foil, e.g. PE (Polyethylene or injection molded plates made from polyurethane); or
    • (b) Film forming by transporting solution through catheter tubes (ID 1-3 mm or any other geometry). The polymerized film was then examined by scanning electron microscopy (see FIG. 1).
EXAMPLE 2
Step 1:
    • 0.45 g SMA 422
    • 23.7 g polyol (VP51 Bayer Co.)
    • 15.9 g isocyanate (Desmodur PF Bayer Co.)
    • Isocyanate and SMA 422 were allowed to react together for up to 10 min. at 60° C. Polyol was then added and the reaction further carried out as in Example 1, Step 2.
    • Mixing and degassing at room temperature.
      Step 2:
    • Casting as film (described above) or potting.
Other reactions of OH-groups on PL-PDMS-PL are well-known in the art and can be exploited for incorporating hydrophobic blocks into a film-forming polymer. The reaction for PL-PDMS-PL can be augmented by reaction with coupling reagents which can then react with functional groups present in other polymers or monomers. Coupling to monomers or prepolymers having —OH functional groups can be carried out using alkyl or aryl sulfonates, e.g. tosylchloride which can be reacted with the monomer or prepolymer, R—OH, then substituted by a OH-group of PL-PDMS-PL.
Monomers or prepolymers having an amine, thiol or alcohol functional group can be activated by cyanuric chloride, then coupled to PL-PDMS-PL. Monomers or prepolymers having an epoxy group can be reacted directly with the OH groups of PL-PDMS-PL. Other coupling agents include anhydrides such as maleic anhydride or maleic acid anhydride copolymer, active esters such as N-hydroxy succinimide and esters of carboxylic acids or carboxylic acids activated by various carbodiimides. In general, a wide variety of such coupling reactions is known in the art and can be exploited to incorporate hydrophobic blocks into film-forming polymers, using known reaction conditions.
EXAMPLE 3
Testing/Assessing Thrombogenicity
Films or coated catheter tubes were tested for thrombogenicity assessment using freshly donated human blood. During contact of blood components with the material the kinetic generation of thrombin-anti-thrombin III complex (TAT) was analyzed as an indicator of thrombin formation. Thrombin is the major component in the coagulation circuit, since thrombin is a potent activator for platelets and cleaves fibrinogen to fibrin, which finally leads to a polymerized network, i.e. a clot. TAT was measured by a commercially available ELISA test according to the instruction of the manufacturer (Behring Co., Germany). The comparison of materials/surfaces is done in direct comparison of the modified versus the non-modified polymer system. Accelerated reaction kinetics for TAT indicates less biocompatible, more thrombogenic material.
For details on methodology for thrombogenicity assessment: Deppisch R. et al. (1993) Nephrol. Dial Transplant Supp. 3 (1994)17-23 and Tsai et al. (1994) ASAIO J. 40:M619-M624
In vitro analysis was performed with freshly donated human whole blood. Similar results, i.e. reduction of TAT, was measured for Example 2—SMA in 2 component PUR.
TABLE I
TAT data for SMA-PUR coated tubes according to Example 1.
TAT TAT TAT TAT
Types (ug/ml) (ug/ml) (ug/ml) (ug/ml)
Blood contact time t = 21 min t = 42 min t = 81 min t = 81 min
Non-treated
2 251 1570 clot already
formed
Treated (60% solvent/ 1 73 605 1313
5% SMA, 35% E22
Treated (50% solvent/ 1 1 54  65
5% SMA, 45% E22
EXAMPLE 4
Si/PDMS Surface Concentration (XPS)
In order to assess the presence of Si, the central component in PDMS molecule x-ray fluorescence spectroscopy was applied. The technique used was described before, e.g. for PVC-SMA mixtures by Tsai et al. (1994) ASAIO J., 40:M619-M624.
Results for films containing no or 3% SMA (related to isocyanate compound) were obtained for different take-off angles (TOA), i.e. 10, 45 and 90°. It is important to note the greater the take-off angle the higher is the penetration depth for the analysis.
TABLE II
Atom (%) Atom (%) Atom (%)
Types TOA 10° TOA 45° TOA 90°
Ex. 1 product non-treated 0 0 0
Ex. 1 product treated 3% SMA 17.9 12.4 9.62

These data show that Si, due to the presence of PDMS-content in the SMA-PUR, increased with decreasing TOA which indicates enrichment of SMA-PUR when cast as described above. In the given example an approximate 20-fold enrichment was realized. This experiment demonstrates that enrichment of the PDMS occurs in the surface.
TABLE III
Atom (%) Atom (%) Atom (%)
Types TOA 10 TOA 45 TOA 90
PUR 2 component non-treated 0 0 0
PUR 2 component treated (3% 15.7 8.2 6.0
SMA)

These data confirm the enrichment of SMA-PUR polymer chains to the uppermost surface.
EXAMPLE 5
Scanning Electron Microscopy (SEM)
Non-modified and SMA-modified films on catheter tubes prepared as cross-cuts were sputter coated with a thin Pt/Au layer and analyzed in a Philips electron microscope. As shown in FIG. 1, a coating film of approximately 20 μm forms labeled “SMA-PUR coating.” The coating process allows variation of the film thickness optimally from about 0.1 μm to several 100 μm. Furthermore, SEM also identifies small white spots which are due to the addition of BaSO4 into the catheter material. BaSO4 gives a change in emission of electrons in SEM. FIG. 1 shows a clear separation of the BaSO4 from the blood contacting surface. As a conclusion: coated, blood-contacting surface lacks roughness due to BaSO4 crystals, there is no release of BaSO4 into blood, instead BaSO4 remains in the catheter material.
EXAMPLE 6
AFM Pictures in Tapping Mode
The next issue in analysis was the confirmation of hypothesized nano-domains. Atomic force microscopy (AFM) is the most powerful technique to analyze nano-structures consisting of patches with different chemical or physico-chemical properties.
The AFM analysis was performed applying tapping mode technique with low forces on the tip of the cantilever (reference for methods: Magonov et al. (1996) in Surface Analysis with STM and AFM, VCH, Weinheim), see FIG. 2 and FIG. 3.
The pictures of the surfaces taken or generated by AFM in tapping show different spots in the size of nanometers (10-100 nm in diameter). The picture defined as height image shows a kind of depth profile, whereas the picture defined as phase shift image shows the phase shift when the cantilever or tip is ‘scratching’ or moving on the surfaces (e.g. due to chemical forces or different softness). Light areas are more soft and hydrophilic. Darker areas have higher PDMS and are harder. By varying the molecular weight or chain length of the coating polymers, the person of ordinary skill in the art can readily modify the lateral structure of the nanodomain morphology.
EXAMPLE 7
Bacterial Adhesion
Evaluation of bacterial adhesion to co-polymer films and coated test plates was conducted by the method of Bechert, T. et al. (1998), XIth Aachen Colloquium on Biomaterials, Poster 26., German Offenlegung DE 19751581 A1. Adhesion of Staphylococcus epidermis on the material surface was quantified by means of photometry using an ELISA reaction to fix a dye to cells adhering on the surface of the material. Optical density measurements provide a relative quantitative measurement of adherent bacteria, under standardized conditions.
Various combinations of polyurethane (PUR) films, co-polymer films of PUR and PL-PDMS-PL, polyurethane test plates uncoated and coated with co-polymer films were tested.
Test plates were made of Tecoflex EG60DB20 (Thermedics, Inc., Woburn, Mass.) a thermoplastic, aliphatic polyurethane synthesized of methylene bis (cyclohexyl) diisocyanate (40%), polytetramethylene ether glycol (9.6%) and 1,4 diol chain extender (30.4%) with barium sulfate (20.0%) to impart x-ray opacity. Coating material was a one-component polyurethane essentially as in Example 1 formed from 35% Demodur E22, 5% PL-PDMS-PL (Tegomer) and 60% methyl isobutyl ketone (MIBK), cast as a film or coated on the Tecoflex test plates.
Test plates or films were exposed to a viable culture of S. epidermis for a period of 48 hours, with absorbance readings every twenty minutes.
Results are shown in FIG. 4. Optical density is plotted on the vertical axis against time on the horizontal axis, for a series of test replicates A-F. Uncoated plates (row 3) rapidly and reproducibly supported increasing density of adherent bacteria. Coated plates over the same time interval did not support measurable bacterial adherence. Films formed of polyurethane alone did not support measurable adherence. Co-polymer films of PUR and PL-PDMS-PL significantly retarded the adherence of bacteria compared to uncoated test plates, by an average of about 30 hours for the same optical density. Surprisingly the presence of PDMS at the surface reduces in a dose-dependent manner the bacterial adhesion and proliferation.
EXAMPLE 8
Cell Toxicity Studies
The toxicity of various combinations of test plate materials, film coatings and film-coated test plates was evaluated by measuring inhibition of cell growth (ICG). ICG was measured by making aqueous eluates of the various test materials, then incubating growing mammalian cells in culture medium containing the eluate, then evaluating cell viability by neutral red uptake.
The ICG test was begun by seeding a 96-well tissue culture plate with 1500-2000 mouse fibroblast cells (strain L-929) previously grown to subconfluence for 48-72 h in complete Eagles MEM. The plates were incubated for 24 h at 37° C. The medium was then removed and test eluates were added. The test eluates were made by incubating test plates or films in distilled water (1 ml for each 10 cm2 test material) at 70° C. for 24 h.
For each plate, 250 μl 0.4% Neutral red solution was mixed with 20 ml of complete Eagle's MEM. The eluate incubation medium was removed and 200 μl/well of neutral red containing medium was added. The plates were then incubated for 3 h at 37° C. The solution was then discarded, the plates rinsed with 200 μl PBS/well. After that, 200 μl/well of 50% (v/v) ethanol and 1% (v/v) acetic acid in distilled water was added. After a 10 min wait the absorbance at 540 nm of each well was measured. ICG % was calculated as A k - A T A k × 100
where AT=mean absorbance in test solution minus mean absorbance in blank, Ak=mean absorbance in control (no cells) minus mean absorbance in blank. The materials are deemed non-toxic if ICG is <30% as described by Wieslander et al. (1991) Kidney International 49:77-79.
The following materials were employed:
Completed Eagles MEM:
    • 500 ml Eagles MEM
    • 50 ml Fetal calf serum
    • 5 ml 200 m ML-Glutamine
    • 5 ml Non-Essential Amino Acid solution.
    • 0.5 ml Gentamycin 50 mg/ml
PBS (10× stock solution):
NaCl 80 g
KCl  2 g
KH2PO4  2 g
Na2HPO4 11 g

dissolve in H2O to 1000 ml final volume.
The stock solution is diluted 10-fold and pH adjusted to 7.2.
50% ethanol, 1% acetic acid solution:
    • 500 ml ethanol (96%)
    • 490 ml water
    • 10 ml Glacial acetic acid
4% Neutral red stock solution:
    • 4 g Neutral red (Merck No.1376)
    • 100 ml distilled water
    • Diluted 10-fold with water prior to use.
In parallel experiments uncoated Tecoflex catheters and co-polymer films were non-toxic, i.e. ICG<30% compared to water or saline solution as reference. However, catheters and test plates coated with co-polymer films were toxic. Substituting Desmodur E23 for Desmodur E22 resulted in co-polymer films which were non-toxic as films and non-toxic when applied to a catheter or test plate. Desmodur E23 has 15%-NCO groups.
Toxicity was also reduced or eliminated by interposing an interlayer of polyol or PL-SMA-PL over the test material, prior to applying the co-polymer film. Test catheters were pre-coated with either 0.125% or 1.0% PL-PDMS-PL by applying the pre-coating in a solution of methyl-isobutyl ketone and curing at 40° C. to remove the solvent. Test catheters were then coated with co-polymer essentially as described in Example 1 except the co-polymer starting solution was 45% Desmodur E23, 5% PL-PDMS-PL and 50% MBK. The data are shown in FIG. 5. Catheters pre-coated with a PL-PDMS-PL interlayer had significantly reduced toxicity although catheters coated without an interlayer were also below the 30% ICG threshold for toxicity. Therefore, toxicity can be reduced either by interposing an interlayer having free-OH groups, or by employing rapidly reacting components to form the co-polymer film. Either strategy avoids or minimizes the possibility of reaction between the reaction components of the co-polymer film and the base polymer of which the article to be coated is formed. This multilayer concept as described above allows a great flexibility in composing the polymers.
EXAMPLE 9
Non-Attachment of Mammalian Cells
The failure of mammalian cells, such as fibroblasts, to attach and overgrow articles coated with a co-polymer film of the present invention was demonstrated in the following way: Fibroblast cells were inoculated on a tissue culture plate pre-coated on the bottom with a co-polymer film of the invention, a portion of which was overlaid by a glass plate with the entire apparatus bathed in growth medium. Growth on the co-polymer surface was compared to growth on the glass surface. Cells grew on the glass surface but failed to attach or proliferate on the co-polymer surface. The failure of cells to attach or proliferate on co-polymer film surfaces of the invention indicates that such surfaces are unlikely to be damaged when implanted, by ingrowth or overgrowth of host cell tissue.
The invention having been described by examples of specific embodiments of the operating principals of the invention, other embodiments will be recognized by those skilled in the art following the general teachings and principles taught or suggested herein. Those variations that fall within the scope of the invention include the use of alternative materials for forming the co-polymer films of the invention, alternative reaction conditions for film formation and/or coating, alternatives for interlayer formation or combinations thereof.
Summary of the Results:
The described SMA-PUR films show a series of improvements in terms of properties:
  • 1. Mechanical stability of the film compared to a simple coating of PL-PDMS-PL;
  • 2. Reduced roughness below 0.1 nm compared to technology used up to now;
  • 3. Micro/Nano-domains in the range of 5-100 nm as proven by AFM:
  • 4. Reduced thrombogenicity: lower TAT generation kinetics; and
  • 5. Enrichment of PDMS to the surface as documented by ESCA and XPS analysis.

Claims (16)

1. A co-polymer film comprising a film-forming polymer component and a hydrophobic polymer block having reactive end groups, said film having a non-uniform surface characterized by domains of varied properties of hydrophobicity, roughness, hardness or other physico-chemically distinct patches, said domains having average diameters in the range 0.1 nm-100 nm, wherein the film-forming polymer is selected from the group consisting of polyurethanes, polyolefins, cellulosic polymers, polycarbonates, polyarylethersulfones, polysulfones, polyvinylchlorides, and polyamides, and the hydrophobic polymer block is selected from the group consisting of siloxane polymers, fluoropolymers, polyethyleneglycol-polydimethyl siloxane co-polymers, silicone polyesters and polylactone-polysiloxane-polylactone triblock co-polymers.
2. The co-polymer film of claim 1 wherein the film-forming polymer is a polyurethane and the hydrophobic polymer block is a polylactone-polysiloxane-polylactone triblock co-polymer.
3. The co-polymer film of claim 1 wherein the film-forming polymer is a polydiphenyl methane diisocyanate prepolymer and the hydrophobic block is a polycaprolacton-polydimethylsiloxane-polycaprolactone triblock co-polymer.
4. The film of claim 3 wherein prior to condensation, the proportion of —OH groups on the hydrophobic block to —NCO groups on the film-forming polymer is in the range of 0.1 to 10.0.
5. A method of making a co-polymer film comprising the steps of:
a) combining a film-forming polymer component and a hydrophobic polymer block having end groups reactive with the film-forming polymer component in the presence of a solvent such that all components are dissolved in the solvent, wherein the film-forming polymer is selected from the group consisting of polyurethanes, polyolefins, cellulosic polymers, polycarbonates, polyarylethersulfones, polysulfones, polyvinylchlorides, and polyamides, and the hydrophobic polymer block is selected from the group consisting of siloxane polymers, fluoropolymers, polyethylenealycol-polydimethyl siloxane co-polymers, silicone polyesters and polylactone-polysiloxane-polylactone triblock co-polymers;
(b) applying the components dissolved in the solvent to a surface to be coated; and
(c) forming a film over the surface to be coated under conditions that allow the solvent to evaporate and the components to react with one another,
whereby a co-polymer film having a non-uniform surface characterized by domains of varied properties of hydrophobicity, roughness, hardness or other physico-chemically distinct patches, and said domains having average diameters in the range 0.1 nm-100 nm, is obtained.
6. The method of claim 5 wherein the film-forming polymer component is a polyurethane-forming component and the hydrophobic block is a polylactone-polysiloxane-polylactone triblock co-polymer.
7. The method of claim 6 wherein, prior to reaction, the proportion of —OH groups on the hydrophobic block to —NCO groups on the film-forming polymer is in the range from 0.1 to 10.0.
8. A The method of claim 6 where in the film-forming polymer component consists essentially of a mixture of an isocyanate and a polyol.
9. The method of claim 5 wherein the step of applying the components dissolved in the solvent to a surface to be coated is carried out by immersing an article to be coated by the film in the solution, then removing the article to permit the solvent to evaporate.
10. The method of claim 5 wherein the surface to be coated has been pre-coated with a layer comprising a polyol, or a polylactone-polysiloxane-polylactdone triblock co-polymer.
11. A method of coating a surface with a biocompatible co-polymer film comprising the steps of:
(a) covering the surface with a solution comprising a film-forming polymer component and a hydrophobic polymer block component having end groups reactive with the film-forming polymer component, the components being dissolved in a solvent, wherein the film-forming polymer is selected from the group consisting of polyurethanes, polyolefins, cellulosic polymers, polycarbonates, polyarylethersulfones, polysulfones, polyvinylchlorides, and polyamides, and the hydrophobic polymer block is selected from the group consisting of siloxane polymers, fluoropolymers, polyethyleneglycol-polydimethyl siloxane co-polymers, silicone polyesters and polylactone-polysiloxane-polylactone triblock co-polymers; and
(b) removing the solvent from the solution covering the surface to allow the components react with one another, whereby a co-polymer film having a non-uniform surface characterized by domains of varied properties of hydrophobicity, roughness, hardness or other physico-chemically distinct patches, and said domains having average diameters in the range 0.1 nm-100 nm, is formed on the surface.
12. The method of claim 11 wherein the film-forming polymer component is a polyurethane-forming component and the hydrophobic block is a polylactone-polysiloxane-polylactone triblock co-polymer.
13. The method of claim 12 wherein prior to reaction, the proportion of —OH groups on the hydrophobic block to —NCO groups on the film-forming polymer is in the range from 0.1 to 10.0.
14. The method of claim 12 wherein the film-forming polymer component consists essentially of a mixture of an isocyanate and a polyol.
15. The method of claim 11 wherein the surface has been pre-coated with a layer comprising a polyol, or a polylactone-polysiloxane-polylactone triblock co-polymer.
16. The method of claim 15 comprising the added step of forming a film over the pre-coating, prior to forming the bio-compatible co-polymer film.
US10/245,115 1998-10-13 2002-09-17 Biocompatible polymer film Expired - Lifetime US6841255B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/245,115 US6841255B2 (en) 1998-10-13 2002-09-17 Biocompatible polymer film

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10400198P 1998-10-13 1998-10-13
US09/415,943 US6500549B1 (en) 1998-10-13 1999-10-08 Biocompatible polymer film
US10/245,115 US6841255B2 (en) 1998-10-13 2002-09-17 Biocompatible polymer film

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/415,943 Division US6500549B1 (en) 1998-10-13 1999-10-08 Biocompatible polymer film

Publications (2)

Publication Number Publication Date
US20030059620A1 US20030059620A1 (en) 2003-03-27
US6841255B2 true US6841255B2 (en) 2005-01-11

Family

ID=22298163

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/415,943 Expired - Lifetime US6500549B1 (en) 1998-10-13 1999-10-08 Biocompatible polymer film
US10/245,115 Expired - Lifetime US6841255B2 (en) 1998-10-13 2002-09-17 Biocompatible polymer film

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/415,943 Expired - Lifetime US6500549B1 (en) 1998-10-13 1999-10-08 Biocompatible polymer film

Country Status (13)

Country Link
US (2) US6500549B1 (en)
EP (1) EP1037679B1 (en)
JP (1) JP4121708B2 (en)
KR (1) KR100656251B1 (en)
CN (1) CN100340311C (en)
AT (1) ATE399573T1 (en)
AU (1) AU1070600A (en)
CA (1) CA2312370C (en)
DE (1) DE69939005D1 (en)
ES (1) ES2308853T3 (en)
HK (1) HK1031344A1 (en)
TW (1) TWI244927B (en)
WO (1) WO2000021585A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071988A1 (en) * 2002-10-11 2004-04-15 Nawrocki Jesse G. Medical devices having durable and lubricious polymeric coating
US20050009208A1 (en) * 2003-06-24 2005-01-13 Carpenter Steven E. Nanostructure fabrication using microbial mandrel
US20050226993A1 (en) * 2000-10-03 2005-10-13 Nawrocki Jesse G Medical devices having durable and lubricious polymeric coating
US20090035350A1 (en) * 2007-08-03 2009-02-05 John Stankus Polymers for implantable devices exhibiting shape-memory effects
US20090259297A1 (en) * 2008-04-10 2009-10-15 Yunbing Wang Implantable Medical Devices Fabricated From Polyurethanes With Grafted Radiopaque Groups
US20100286766A1 (en) * 2009-05-08 2010-11-11 Greatbatch, Ltd. Surface modification for coating
US20100294363A1 (en) * 2009-05-22 2010-11-25 Mitsubishi Polyester Film, Inc. Coated Polyester Film For Lamination to Ethylene-Vinyl Acetate Layers
US20180243717A1 (en) * 2015-07-05 2018-08-30 Universidade Do Minho Micro- or nanocapsules having photocatalytic properties for controlled release of diffusing agents and respective method of production
USD907771S1 (en) 2017-10-09 2021-01-12 Pioneer Surgical Technology, Inc. Intervertebral implant
US11147682B2 (en) 2017-09-08 2021-10-19 Pioneer Surgical Technology, Inc. Intervertebral implants, instruments, and methods

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605221B2 (en) * 1999-05-18 2009-10-20 Sabic Innovative Plastics Ip B.V. Weatherable, thermostable polymers having improved flow composition
US7169859B2 (en) * 1999-05-18 2007-01-30 General Electric Company Weatherable, thermostable polymers having improved flow composition
US7790292B2 (en) 1999-05-18 2010-09-07 Sabic Innovative Plastics Ip B.V. Polysiloxane copolymers, thermoplastic composition, and articles formed therefrom
FR2812297B1 (en) 2000-07-28 2006-06-16 D Applic Nouvelles De Procedes NOVEL THERMOSETTING ELASTOMER COMPOSITION BASED ON MODIFIED POLYCYANURATE WITH IMPROVED THERMAL STRENGTH
WO2004076541A2 (en) * 2003-02-21 2004-09-10 General Electric Company Translucent thermoplastic composition, method for making the composition and articles molded there from.
SE526027C2 (en) * 2003-05-23 2005-06-14 Gambro Lundia Ab Biocompatible polymer composition with antibacterial properties, useful e.g., in medical devices, wound dressings, and food and medicine storage containers, comprises a bismuth complex such as triphenylbismuth dichloride
JP2006522172A (en) * 2003-05-23 2006-09-28 ガンブロ・ルンディア・エービー Biocompatible polymer
US7169404B2 (en) * 2003-07-30 2007-01-30 Advanced Cardiovasular Systems, Inc. Biologically absorbable coatings for implantable devices and methods for fabricating the same
CA2540382C (en) * 2003-09-29 2012-03-06 Hemoteq Gmbh Biocompatible, biostable coating of medical surfaces
DE102004020856A1 (en) * 2003-09-29 2005-04-14 Hemoteq Gmbh Medical product coated with biostable layer of polysulfone, useful particularly as stent for preventing restenosis, controls kinetics of release of incorporated active agents, e.g. antiproliferative agents
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US7135538B2 (en) 2003-11-12 2006-11-14 General Electric Company Transparent polycarbonate-polysiloxane copolymer blend, method for the preparation thereof, and article derived therefrom
DE102004025130A1 (en) * 2004-05-18 2005-12-08 Universitätsklinikum Hamburg-Eppendorf Körperschaft des Öffentlichen Rechts Method and device for investigating sludgeal deposits on materials for endoprostheses and endoprosthesis
US8062729B2 (en) * 2005-01-14 2011-11-22 Ndsu Research Foundation Polymeric material with surface microdomains
WO2006102233A2 (en) * 2005-03-18 2006-09-28 Immunivest Corporation Method and apparatus for imaging target components in a biological sample using permanent magnets
US7771833B2 (en) * 2005-05-09 2010-08-10 Ndsu Research Foundation Anti-fouling materials containing cationic polysiloxanes
US7799434B2 (en) * 2005-07-29 2010-09-21 Ndsu Research Foundation Functionalized polysiloxane polymers
US7989074B2 (en) * 2006-06-09 2011-08-02 Ndsu Research Foundation Thermoset siloxane-urethane fouling release coatings
US8372384B2 (en) * 2007-01-08 2013-02-12 Ndsu Research Foundation Quaternary ammonium functionalized cross-linked polyalkylsiloxanes with anti-fouling activity
US20080188830A1 (en) * 2007-02-06 2008-08-07 Arrow International, Inc. Selectively reinforced medical devices
US8299200B2 (en) * 2007-06-11 2012-10-30 Ndsu Research Foundation Anchored polysiloxane-modified polyurethane coatings and uses thereof
US8053535B2 (en) * 2007-07-11 2011-11-08 Ndsu Research Foundation Polysiloxanes with anti-fouling activity
US8110101B2 (en) * 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US7828968B2 (en) * 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US8709394B2 (en) * 2007-09-28 2014-04-29 Ndsu Research Foundation Antimicrobial polysiloxane materials containing metal species
CN101176800B (en) * 2007-10-13 2011-07-13 山东新华医疗器械股份有限公司 Lustering conserve oil for medical instruments and preparation method thereof
US8071706B2 (en) 2008-02-13 2011-12-06 Ndsu Research Foundation Siloxane polymer containing tethered levofloxacin
US20100004202A1 (en) * 2008-02-15 2010-01-07 Ndsu Research Foundation Quaternary ammonium-functionalized-POSS compounds
CN101234748B (en) * 2008-02-27 2010-06-16 吉林大学 Method for constructing polymer ordered micro-configuration
US8916188B2 (en) 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
ES2687650T3 (en) 2008-04-25 2018-10-26 Northwestern University Lithography of Polymer Feathers
US20100082097A1 (en) * 2008-10-01 2010-04-01 Joel Rosenblatt Article Containing Segregated Biguanide and Lewis Acid
WO2010096593A2 (en) 2009-02-18 2010-08-26 Northwestern University Beam pen lithography
US8961853B2 (en) 2009-06-05 2015-02-24 Northwestern University Silicon pen nanolithography
US8745761B2 (en) * 2009-12-07 2014-06-03 Northwestern University Force feedback leveling of tip arrays for nanolithography
WO2011071753A2 (en) 2009-12-07 2011-06-16 Northwestern University Generation of combinatorial patterns by deliberate tilting of a polymer-pen array
EP2821422A3 (en) 2010-03-09 2015-05-06 Polymers CRC Ltd. Polyurethane block copolymer based on poly siloxane tenside for membranes
WO2012125986A1 (en) 2011-03-17 2012-09-20 Northwestern University Method of analyzing an analyte using combinatorial arrays and uniform patterns
CN104903793A (en) 2012-10-29 2015-09-09 西北大学 Heat actuated and projected lithography systems and methods
EP3019557B1 (en) * 2013-07-12 2018-09-05 PolyOne Corporation Polyester compounds having enhanced hydrophobic surface properties
US10203598B2 (en) 2015-10-16 2019-02-12 Northwestern University Gradient spray coating polymer pen arrays
US9971239B2 (en) 2015-10-22 2018-05-15 Northwestern University Silica polymer pen lithography
CN109414874A (en) 2016-05-31 2019-03-01 西北大学 Method and apparatus for manufacturing three-dimension object
US10563244B2 (en) 2016-09-20 2020-02-18 Northwestern University Nanopatterned extracellular matrices enable cell-based assays with a mass spectrometric readout
EP3552027B1 (en) 2016-12-07 2023-05-03 Northwestern University Liquid masks for microfabrication processes
CN109762333B (en) * 2018-12-29 2021-05-25 苏州大学 Modified cyanate ester cast plate
EP3930773B1 (en) * 2019-03-01 2023-03-01 DSM IP Assets B.V. Medical implant component comprising a composite biotextile and method of making
CN110124115B (en) * 2019-04-11 2021-04-02 复旦大学 Hydrophobic coating, preparation method and application thereof, and absorbable implantable device
CN110075369B (en) * 2019-04-11 2020-11-06 复旦大学 Metal-polymer composite stent capable of regulating degradation rate by multilayer design and preparation method and application thereof
CN113493558A (en) * 2020-03-18 2021-10-12 微泰医疗器械(杭州)有限公司 Triblock copolymer for implantable biosensor and application and preparation method thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582423A (en) 1966-12-19 1971-06-01 Wilmington Chem Corp Process for coating porous substrates
US4242474A (en) 1978-10-04 1980-12-30 Terumo Corporation Production of a block copolymer containing hydrophilic and hydrophobic blocks
US4861830A (en) 1980-02-29 1989-08-29 Th. Goldschmidt Ag Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming
US4945148A (en) 1989-03-06 1990-07-31 General Electric Company Silicone-polycarbonate block copolymers
US5179142A (en) 1989-06-02 1993-01-12 Shin-Etsu Chemical Company, Limited Polylactone-modified organopolysiloxane compounds
US5266645A (en) 1990-12-22 1993-11-30 Roehm Gmbh Chemische Fabrik Acrylate-methacrylate graft polymerizate
US5312652A (en) 1991-06-04 1994-05-17 Sollac Process for forming a copolymer-based anticorrosion coating on a metal surface and the products thus obtained
US5589563A (en) 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
US5702823A (en) 1994-04-15 1997-12-30 Cobe Laboratories, Inc. Biocompatible coated article
US5863627A (en) 1997-08-26 1999-01-26 Cardiotech International, Inc. Hydrolytically-and proteolytically-stable polycarbonate polyurethane silicone copolymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5781347A (en) * 1980-11-10 1982-05-21 Nippon Zeon Co Blood contact medical appliance having antithrombus property and its manufacture
JP2687319B2 (en) * 1988-10-06 1997-12-08 竹本油脂株式会社 Impact resistance improving agent for polyester resin and polyester resin composition containing the improving agent
US5378902A (en) * 1993-09-02 1995-01-03 The Regents Of The University Of Colorado Optoelectronic maximum identifier for detecting the physical location of a maximum intensity optical signal in a winner-take-all network
DE69625822T2 (en) * 1995-05-01 2003-06-05 Samyang Corp IMPLANTABLE, BIORESORBABLE MEMBRANE AND METHOD FOR THE PRODUCTION THEREOF
DE19539290A1 (en) * 1995-10-23 1997-04-24 Bayer Ag Process for the preparation of poly (diorganosiloxane) -polycarbonate block copolymers
AUPO538397A0 (en) * 1997-02-28 1997-03-27 University Of Wollongong, The Hydrodynamic electroprocessing of soluble conducting polymers

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582423A (en) 1966-12-19 1971-06-01 Wilmington Chem Corp Process for coating porous substrates
US4242474A (en) 1978-10-04 1980-12-30 Terumo Corporation Production of a block copolymer containing hydrophilic and hydrophobic blocks
US4861830A (en) 1980-02-29 1989-08-29 Th. Goldschmidt Ag Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming
US4945148A (en) 1989-03-06 1990-07-31 General Electric Company Silicone-polycarbonate block copolymers
EP0386547A2 (en) 1989-03-06 1990-09-12 General Electric Company Silicone-polycarbonate block copolymers
US5179142A (en) 1989-06-02 1993-01-12 Shin-Etsu Chemical Company, Limited Polylactone-modified organopolysiloxane compounds
US5266645A (en) 1990-12-22 1993-11-30 Roehm Gmbh Chemische Fabrik Acrylate-methacrylate graft polymerizate
US5312652A (en) 1991-06-04 1994-05-17 Sollac Process for forming a copolymer-based anticorrosion coating on a metal surface and the products thus obtained
US5589563A (en) 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
US5702823A (en) 1994-04-15 1997-12-30 Cobe Laboratories, Inc. Biocompatible coated article
US5738902A (en) 1994-04-15 1998-04-14 Cobe Laboratories, Inc. Biocompatible coated article
US5863627A (en) 1997-08-26 1999-01-26 Cardiotech International, Inc. Hydrolytically-and proteolytically-stable polycarbonate polyurethane silicone copolymers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Costerton, JW et al. (1999), "Bacterial Biofilms: A Common Cause of Presistent Infections;" Science 284:1318-1322.
Deppisch, R et al. (1998), "Microdomain Structure of Polymeric Surfaces-Potential for Improving Blood Treatment Procecures;" Nephrol. Dial. Transdplant 13:1354-1359.
Tezuka, Y et al. (1991), "Environmentally Induced Macromolecular Rearrangement on the Surface of Polyurethane-Polysiloxane Block Copolymers;" J. Chem. Soc. 87(1):147-152.

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226993A1 (en) * 2000-10-03 2005-10-13 Nawrocki Jesse G Medical devices having durable and lubricious polymeric coating
US20090264912A1 (en) * 2000-10-03 2009-10-22 Nawrocki Jesse G Medical devices having durable and lubricious polymeric coating
US7041088B2 (en) * 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
US20040071988A1 (en) * 2002-10-11 2004-04-15 Nawrocki Jesse G. Medical devices having durable and lubricious polymeric coating
AU2003252885B2 (en) * 2002-10-11 2008-08-21 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
US6921670B2 (en) * 2003-06-24 2005-07-26 Hewlett-Packard Development Company, Lp. Nanostructure fabrication using microbial mandrel
US20050009208A1 (en) * 2003-06-24 2005-01-13 Carpenter Steven E. Nanostructure fabrication using microbial mandrel
US9066992B2 (en) 2007-08-03 2015-06-30 Abbott Cardiovascular Systems Inc. Polymers for implantable devices exhibiting shape-memory effects
US20090035350A1 (en) * 2007-08-03 2009-02-05 John Stankus Polymers for implantable devices exhibiting shape-memory effects
US9259515B2 (en) 2008-04-10 2016-02-16 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from polyurethanes with grafted radiopaque groups
US20090259297A1 (en) * 2008-04-10 2009-10-15 Yunbing Wang Implantable Medical Devices Fabricated From Polyurethanes With Grafted Radiopaque Groups
US20100286766A1 (en) * 2009-05-08 2010-11-11 Greatbatch, Ltd. Surface modification for coating
US9289540B2 (en) 2009-05-08 2016-03-22 Greatbatch Ltd. Surface modification for coating
US20100294363A1 (en) * 2009-05-22 2010-11-25 Mitsubishi Polyester Film, Inc. Coated Polyester Film For Lamination to Ethylene-Vinyl Acetate Layers
US20180243717A1 (en) * 2015-07-05 2018-08-30 Universidade Do Minho Micro- or nanocapsules having photocatalytic properties for controlled release of diffusing agents and respective method of production
US11147682B2 (en) 2017-09-08 2021-10-19 Pioneer Surgical Technology, Inc. Intervertebral implants, instruments, and methods
USD907771S1 (en) 2017-10-09 2021-01-12 Pioneer Surgical Technology, Inc. Intervertebral implant
USD968613S1 (en) 2017-10-09 2022-11-01 Pioneer Surgical Technology, Inc. Intervertebral implant

Also Published As

Publication number Publication date
US20030059620A1 (en) 2003-03-27
JP2002527534A (en) 2002-08-27
TWI244927B (en) 2005-12-11
DE69939005D1 (en) 2008-08-14
EP1037679A1 (en) 2000-09-27
AU1070600A (en) 2000-05-01
US6500549B1 (en) 2002-12-31
JP4121708B2 (en) 2008-07-23
KR20010033076A (en) 2001-04-25
EP1037679B1 (en) 2008-07-02
KR100656251B1 (en) 2006-12-12
CA2312370C (en) 2009-05-19
ATE399573T1 (en) 2008-07-15
CN100340311C (en) 2007-10-03
WO2000021585A1 (en) 2000-04-20
CN1287498A (en) 2001-03-14
CA2312370A1 (en) 2000-04-20
ES2308853T3 (en) 2008-12-01
HK1031344A1 (en) 2001-06-15

Similar Documents

Publication Publication Date Title
US6841255B2 (en) Biocompatible polymer film
Ishihara Revolutionary advances in 2‐methacryloyloxyethyl phosphorylcholine polymers as biomaterials
Hedayati et al. The quest for blood-compatible materials: Recent advances and future technologies
Klee et al. Polymers for biomedical applications: improvement of the interface compatibility
Grasel et al. Surface properties and blood compatibility of polyurethaneureas
Lee et al. Tissue anti-adhesion potential of ibuprofen-loaded PLLA–PEG diblock copolymer films
Nagaoka et al. Low-friction hydrophilic surface for medical devices
Legeay et al. New surfaces with hydrophilic/hydrophobic characteristics in relation to (no) bioadhesion
KR20160100057A (en) Surface-modified biomaterials by biocompatible polymer containing adhesive catechol derivative and preparing method thereof
Hou et al. Facile preparation of medical segmented poly (ester-urethane) containing uniformly sized hard segments and phosphorylcholine groups for improved hemocompatibility
Kim et al. UV-induced graft copolymerization of monoacrylate-poly (ethylene glycol) onto poly (3-hydroxyoctanoate) to reduce protein adsorption and platelet adhesion
Kondyurina et al. Plasma mediated protein immobilisation enhances the vascular compatibility of polyurethane with tissue matched mechanical properties
Jones et al. Sequential polyurethane–poly (methylmethacrylate) interpenetrating polymer networks as ureteral biomaterials: mechanical properties and comparative resistance to urinary encrustation
Yaseen et al. Dynamic protein adsorption at the polyurethane copolymer/water interface
Braune et al. Interaction of thrombocytes with poly (ether imide): The influence of processing
Khanna Fabrication of human serum albumin film for enhanced hemocompatibility and mitigation of neointimal hyperplasia under physiologically relevant flow shear conditions
Eastmond et al. Biomedical applications polymer blends
JP4097762B2 (en) Antithrombotic medical material
JP2006501346A (en) Process for producing polysiloxane-polyurethane elastomer block copolymer and use thereof
Kennedy Novel designed polyisobutylene-based biopolymers: synthesis, characterization, and biological testing of amphiphilic chameleon networks
US20220049098A1 (en) Zwitterionic Polysiloxane for Biomedical Devices
Kyomoto et al. Phospholipid Polymer-Grafted Poly (Ether-Ether-Ketone) by Self-Initiated Surface Grafting
Ngo Thromboresistant Silicones and Polyurethanes Prepared with Amphiphilic Surface-modifying Additives
Marques Antifouling surfaces as a strategy to prevent microorganism’s adhesion on medical devices
Legeay et al. Surface engineering by coating of hydrophilic layers: bioadhesion and biocontamination

Legal Events

Date Code Title Description
AS Assignment

Owner name: GAMBRO AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEPPISCH, REINHOLD;BAUER, ULRICH;BECK, WERNER;AND OTHERS;REEL/FRAME:013378/0312;SIGNING DATES FROM 19991014 TO 19991018

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
CC Certificate of correction
AS Assignment

Owner name: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGEN

Free format text: SECURITY AGREEMENT;ASSIGNOR:GAMBRO AB;REEL/FRAME:018552/0672

Effective date: 20061117

AS Assignment

Owner name: GAMBRO LUNDIA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GAMBRO AB;REEL/FRAME:020555/0259

Effective date: 20071019

AS Assignment

Owner name: GAMBRO LUNDIA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GAMBRO AB;REEL/FRAME:020571/0830

Effective date: 20071019

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: GAMBRO AB, COLORADO

Free format text: RELEASE OF SECURITY INTEREST IN PATENTS;ASSIGNOR:CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT;REEL/FRAME:027456/0134

Effective date: 20111207

AS Assignment

Owner name: GAMBRO LUNDIA AB, COLORADO

Free format text: RELEASE OF SECURITY INTEREST IN PATENTS;ASSIGNOR:CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT;REEL/FRAME:027456/0050

Effective date: 20111207

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12